Abcam, ab259089, Human RPL36A knockout HeLa cell lysate

Size: 1Kit
RPL36A KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RPL36A, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RPL36A also known as Ribosomal Protein L36-A or L36A is a component of the 60S ribosomal subunit. This protein has a mass of approximately 12 kDa and is widely expressed in various tissues mainly reflecting its fundamental role in cellular processes. As an essential part of the ribosome RPL36A helps facilitate the translation of messenger RNA into proteins contributing to the protein synthesis machinery which is essential for cell function and proliferation.
Biological function summary
RPL36A is involved in the ribosome's structural integrity and function. It assumes an important role within the ribosomal large subunit by engaging in ribosome assembly and stability. As a part of the ribosomal complex RPL36A contributes to the decoding and translocation phases during protein biosynthesis. Its integration within this complex highlights its significance in cellular metabolism and growth.
Pathways
RPL36A plays an integral part in the translation pathway specifically in the process of translation initiation and elongation. It is actively involved in the assembly of the pre-initiation complex and the elongation cycle. Additionally RPL36A interacts within the mTOR signaling pathway which regulates cell growth and metabolism in response to nutrients growth factors and other stimuli. Through this pathway its relationship with proteins like S6 kinase is noteworthy as they collectively influence protein synthesis rate and cell growth.
Alterations in RPL36A can potentially relate to cancer and Diamond-Blackfan anemia (DBA). Changes in the expression levels or mutations of RPL36A have been implicated in the development of certain cancers where enhanced ribosomal biogenesis supports tumor growth. In DBA a disorder characterized by failure in red blood cell production mutations in ribosomal proteins like RPL36A disrupt ribosome function leading to hematological abnormalities. Interactions with other ribosomal proteins such as RPS19 further illustrate its involvement in the pathogenesis of ribosomopathies.